Get started
MEDINCELL S.A.MEDINCELL S.A.MEDINCELL S.A.

MEDINCELL S.A.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MEDCL chart


Full chart

MEDCL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪505.45 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.08 EUR
Net income (FY)
‪−25.04 M‬ EUR
Revenue (FY)
‪9.03 M‬ EUR
Shares float
‪20.88 M‬
Beta (1Y)
0.58

Employees


Employees (FY)
134
Change (1Y)
−9 −6.29%
Revenue / Employee (1Y)
‪67.40 K‬ EUR
Net income / Employee (1Y)
‪−186.85 K‬ EUR

About MEDINCELL S.A.


Sector
Health Technology
CEO
Christophe Douat
Headquarters
Jacou
Website
medincell.com
Founded
2003
ISIN
FR0004065605
FIGI
BBG00M0C8GJ0
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. It focuses on combining its proprietary BEPO technology with active ingredients already known and marketed; it controls the regular delivery of a drug at the optimal therapeutic dose. The company was founded by Anh Nguyen and Christophe Douat on January 9, 2003 and is headquartered in Jacou, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MEDCL news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MEDCL is 16.80 EUR — it has increased by 3.22% in the past 24 hours. Watch MEDINCELL S.A. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange MEDINCELL S.A. stocks are traded under the ticker MEDCL.
MEDCL stock has risen by 1.76% compared to the previous week, the month change is a −4.31% fall, over the last year MEDINCELL S.A. has showed a 139.66% increase.
We've gathered analysts' opinions on MEDINCELL S.A. future price: according to them, MEDCL price has a max estimate of 25.00 EUR and a min estimate of 22.00 EUR. Watch MEDCL chart and read a more detailed MEDINCELL S.A. stock forecast: see what analysts think of MEDINCELL S.A. and suggest that you do with its stocks.
MEDCL reached its all-time high on Apr 8, 2020 with the price of 20.00 EUR, and its all-time low was 4.34 EUR and was reached on Mar 17, 2020. View more price dynamics on MEDCL chart.
See other stocks reaching their highest and lowest prices.
MEDCL stock is 4.42% volatile and has beta coefficient of 0.58. Track MEDINCELL S.A. stock price on the chart and check out the list of the most volatile stocks — is MEDINCELL S.A. there?
Today MEDINCELL S.A. has the market capitalization of ‪505.67 M‬, it has decreased by −0.24% over the last week.
Yes, you can track MEDINCELL S.A. financials in yearly and quarterly reports right on TradingView.
MEDINCELL S.A. is going to release the next earnings report on Jun 9, 2025. Keep track of upcoming events with our Earnings Calendar.
MEDCL net income for the last half-year is ‪−14.57 M‬ EUR, while the previous report showed ‪−16.88 M‬ EUR of net income which accounts for 13.70% change. Track more MEDINCELL S.A. financial stats to get the full picture.
No, MEDCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 134.00 employees. See our rating of the largest employees — is MEDINCELL S.A. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDINCELL S.A. EBITDA is ‪−20.44 M‬ EUR, and current EBITDA margin is −245.36%. See more stats in MEDINCELL S.A. financial statements.
Like other stocks, MEDCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDINCELL S.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDINCELL S.A. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDINCELL S.A. stock shows the buy signal. See more of MEDINCELL S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.